Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

Anti-TNF drugs have dramatically improved the lives of many patients living with rheumatoid arthritis. Not all patients respond to therapy however, with almost 40% showing a poor response to treatment.  

An alternative treatment to anti-TNF is the targeting of B-cells which are known to contribute to the development of RA by driving synovial inflammationThe B-cell depleting drug rituximab is used after an inadequate response to initial anti-TNF, but in this more therapy-resistant patient cohort, rituximab also shows limited improvement. The research team hypothesised that the number or markers of synovial tissue  B-cells before treatment could be used to predict a response.  

Peter Taylor, the Norman Collisson chair of musculoskeletal sciences at NDORMS said: We wanted to test the levels of B-cells in synovial tissue from patients with rheumatoid arthritis to see whether low or absent levels of the cells were preventing rituximab from working effectively. Against this we wanted to test whether tocilizumab, which works by inhibiting the action of IL-6, protein that can cause inflammation and damage, improved clinical outcomes. Our study was the first biopsy-driven randomised clinical trial in rheumatoid arthritis.” 

The study was a 48-week, biopsy-driven trial done in 19 centres across five European countries. Following a baseline synovial biopsy, patients were classified as B-cell poor or rich, then randomly assigned to receive either rituximab or tocilizumab infusions.  

To enhance the accuracy of the classification of B-cell poor and B-cell rich patients, baseline synovial biopsies from all participants were subjected to RNA sequencing and reclassified by B-cell molecular signature. At 16 weeks, any improvement in Clinical Disease Activity Index was measured in all patients.  

In the synovial biopsies classified as B-cell poor with RNA sequencing the tocilizumab group had a significantly higher response rate compared with the rituximab group.  

“Our trial represents a milestone towards precision rheumatology,” said Peter. “In future, binvestigating disease at the tissue level we can start to tailor our treatment and make the best drug selection for each individual patient’s needs. This may improve clinical response and have a major effect on related health and societal costs while reducing patient exposure to potentially toxic drugs. 

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.